scholarly journals Design and Development of the Brain Training System for the Digital “Maintain Your Brain” Dementia Prevention Trial

JMIR Aging ◽  
10.2196/13135 ◽  
2019 ◽  
Vol 2 (1) ◽  
pp. e13135 ◽  
Author(s):  
Courtney Campbell Walton ◽  
Amit Lampit ◽  
Christos Boulamatsis ◽  
Harry Hallock ◽  
Polly Barr ◽  
...  
Keyword(s):  
Training System ◽  
Prevention Trial ◽  
Brain Training ◽  
Design And Development ◽  
Dementia Prevention ◽  
The Brain

scholarly journals Design and Development of the Brain Training System for the Digital “Maintain Your Brain” Dementia Prevention Trial (Preprint)

2019 ◽  
Author(s):  
Courtney Campbell Walton ◽  
Amit Lampit ◽  
Christos Boulamatsis ◽  
Harry Hallock ◽  
Polly Barr ◽  
...  
Keyword(s):  
Digital Health ◽  
Controlled Trial ◽  
Pilot Trial ◽  
Cognitive Activity ◽  
Training System ◽  
Support Network ◽  
Brain Training ◽  
Design And Development ◽  
Main Trial ◽  
Comparative Feedback

BACKGROUND Dementia is the leading cause of disability worldwide, and interventions aimed at reducing the prevalence and burden of the disease are urgently needed. Maintain Your Brain (MYB) is a randomized controlled trial of a multimodal digital health intervention targeting modifiable dementia risk factors to combat cognitive decline and potentially prevent dementia. In addition to behavioral modules targeting mood, nutrition, and physical exercise, a new Brain Training System (BTS) will deliver computerized cognitive training (CCT) throughout the trial to provide systematic, challenging, and personally adaptive cognitive activity. OBJECTIVE This paper aimed to describe the design and development of BTS. METHODS BTS has been designed with a central focus on the end user. Raw training content is provided by our partner NeuroNation and delivered in several innovative ways. A baseline cognitive profile directs selection and sequencing of exercises within and between sessions and is updated during the 10-week 30-session module. Online trainers are available to provide supervision at different levels of engagement, including face-to-face share-screen coaching, a key implementation resource that is triaged by a “red flag” system for automatic tracking of user adherence and engagement, or through user-initiated help requests. Individualized and comparative feedback is provided to aid motivation and, for the first time, establish a social support network for the user based on their real-world circle of friends and family. RESULTS The MYB pilot was performed from November 2017 to March 2018. We are currently analyzing data from this pilot trial (n=100), which will make up a separate research paper. The main trial was launched in June 2018. Process and implementation data from the first training module (September to November 2018) are expected to be reported in 2019 and final trial outcomes are anticipated in 2022. CONCLUSIONS The BTS implemented in MYB is focused on maximizing adherence and engagement with CCT over the short and long term in the setting of a fully digital trial, which, if successful, could be delivered economically at scale. CLINICALTRIAL Australian New Zealand Clinical Trials Registry ACTRN12618000851268; https://www.anzctr.org.au /Trial/Registration/TrialReview.aspx?id=370631&isReview=true

scholarly journals Design and development of a gait training system for Parkinson’s disease

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0207136 ◽  
Author(s):  
Ainara Garzo ◽  
Paula Alexandra Silva ◽  
Nestor Garay-Vitoria ◽  
Erik Hernandez ◽  
Stephen Cullen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Gait Training ◽  
Training System ◽  
Design And Development

scholarly journals White matter hyperintensities are common in midlife and already associated with cognitive decline

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Tracy d’Arbeloff ◽  
Maxwell L Elliott ◽  
Annchen R Knodt ◽  
Tracy R Melzer ◽  
Ross Keenan ◽  
...  
Keyword(s):  
White Matter ◽  
Cognitive Decline ◽  
White Matter Hyperintensities ◽  
Clinical Symptoms ◽  
White Matter Hyperintensity ◽  
Dementia Prevention ◽  
Increased Risk ◽  
Weighted Magnetic Resonance Imaging ◽  
Intervention Trials ◽  
The Brain

Abstract White matter hyperintensities proliferate as the brain ages and are associated with increased risk for cognitive decline as well as Alzheimer’s disease and related dementias. As such, white matter hyperintensities have been targeted as a surrogate biomarker in intervention trials with older adults. However, it is unclear at what stage of aging white matter hyperintensities begin to relate to cognition and if they may be a viable target for early prevention. In the Dunedin Study, a population-representative cohort followed since birth, we measured white matter hyperintensities in 843 45-year-old participants using T2-weighted magnetic resonance imaging and we assessed cognitive decline from childhood to midlife. We found that white matter hyperintensities were common at age 45 and that white matter hyperintensity volume was modestly associated with both lower childhood (ß = −0.08, P = 0.013) and adult IQ (ß=−0.15, P < 0.001). Moreover, white matter hyperintensity volume was associated with greater cognitive decline from childhood to midlife (ß=−0.09, P < 0.001). Our results demonstrate that a link between white matter hyperintensities and early signs of cognitive decline is detectable decades before clinical symptoms of dementia emerge. Thus, white matter hyperintensities may be a useful surrogate biomarker for identifying individuals in midlife at risk for future accelerated cognitive decline and selecting participants for dementia prevention trials.

scholarly journals IC-02-01: MRI evidence for a disease modifying effect of Ginkgo Biloba extract in a dementia prevention trial

2008 ◽  
Vol 4 ◽  
pp. T4-T4 ◽  
Author(s):  
Jeffrey A. Kaye ◽  
Hiroko Dodge ◽  
Tracy Zitzelberger ◽  
Milar Moore ◽  
Barry Oken
Keyword(s):  
Ginkgo Biloba ◽  
Ginkgo Biloba Extract ◽  
Prevention Trial ◽  
Dementia Prevention ◽  
Modifying Effect ◽  
Disease Modifying

scholarly journals White matter hyperintensities are common in midlife and already associated with cognitive decline

2019 ◽  
Author(s):  
Tracy d’Arbeloff ◽  
Maxwell L. Elliott ◽  
Annchen R. Knodt ◽  
Tracy R. Melzer ◽  
Ross Keenan ◽  
...  
Keyword(s):  
White Matter ◽  
Cognitive Decline ◽  
White Matter Hyperintensities ◽  
Clinical Symptoms ◽  
Early Prevention ◽  
Dementia Prevention ◽  
Increased Risk ◽  
Prevention Trials ◽  
Intervention Trials ◽  
The Brain

AbstractWhite matter hyperintensities (WMHs) proliferate as the brain ages and are associated with increased risk for cognitive decline as well as Alzheimer’s disease and related dementias. As such, WMHs have been targeted as a surrogate biomarker in intervention trials with older adults. However, it is unclear at what stage of aging WMHs begin to relate to cognition and if they may be a viable target for early prevention. In a population-representative birth cohort of 843 45-year-olds we measured WMHs using T2-weighted MRI, and we assessed cognitive decline from childhood to midlife. We found that WMHs were common at age 45 and that WMH volume was modestly associated with both lower childhood (ß=-0.08, p=0.013) and adult IQ (ß=-0.15, p<0.001). Moreover, WMH volume was associated with greater cognitive decline from childhood to midlife (ß=-0.09, p<0.001). Our results demonstrate that a link between WMHs and early signs of cognitive decline is detectable decades before clinical symptoms of dementia emerge. Thus, WMHs may be a useful surrogate biomarker for identifying individuals in midlife at risk for future accelerated cognitive decline and selecting participants for dementia prevention trials.

Sign in / Sign up

Export Citation Format

Share Document